Salarius Pharmaceuticals, Inc. (SLRX) Earnings History
Annual and quarterly earnings data from 2015 to 2024
Loading earnings history...
SLRX EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
SLRX Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | 100.0% | -148.8% | -140.5% |
Download Data
Export SLRX earnings history in CSV or JSON format
Free sign-in required to download data
Salarius Pharmaceuticals, Inc. (SLRX) Earnings Overview
As of May 8, 2026, Salarius Pharmaceuticals, Inc. (SLRX) reported trailing twelve-month net income of -$5M, reflecting -152268.4% year-over-year growth. The company earned $-10.39 per diluted share over the past four quarters.
Looking at the long-term picture, SLRX's historical earnings data spans multiple years. The company achieved its highest annual net income of -$6M in fiscal 2024, representing a new all-time high.
Salarius Pharmaceuticals, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including IMVT (-$464M net income), KROS ($87M net income, 35.7% margin), TPVG (-$12M net income, 50.6% margin), SLRX has comparable earnings metrics. Compare SLRX vs IMVT →
SLRX Earnings vs Peers
Earnings metrics vs comparable public companies
SLRX Historical Earnings Data (2015–2024)
10 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$6M | +55.5% | -$6M | $-86.85 | - | - |
| 2023 | -$13M | +60.3% | -$13M | $-0.06 | - | - |
| 2022 | -$32M | -147.6% | -$32M | $-221.55 | - | - |
| 2021 | -$13M | -73.7% | -$13M | $-930.00 | - | - |
| 2020 | -$7M | -6.0% | -$8M | $-1500.00 | -140.5% | -148.8% |
| 2019 | -$7M | +68.4% | -$8M | $-6360.00 | -200.2% | -238.5% |
| 2018 | -$22M | +36.3% | -$22M | $-91500.00 | -2615.6% | -2633.7% |
| 2017 | -$34M | +12.8% | -$35M | $-149250.00 | -2701.7% | -2724.6% |
| 2016 | -$39M | -35.5% | -$40M | $-182250.00 | -3907.6% | -3946.5% |
| 2015 | -$29M | - | -$29M | $-19468.80 | - | - |
See SLRX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SLRX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SLRX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonSLRX — Frequently Asked Questions
Quick answers to the most common questions about buying SLRX stock.
Is SLRX growing earnings?
SLRX EPS fell to $-10.39, with earnings declining -152268.4%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-5M.
What are SLRX's profit margins?
Salarius Pharmaceuticals, Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are SLRX's earnings?
SLRX earnings data spans 2015-2024. The declining earnings trend is -152268.4% YoY. Historical data enables comparison across business cycles.